MC
AEON icon

Meteora Capital’s AEON Biopharma AEON Stock Holding History

Meteora Capital’s Portfolio AEON Stock Details AEON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4
Closed -$4 – 384
2025
Q4 		$4 Buy
+4
New +$4 ﹤0.01% 403
2023
Q3 		– Sell
-208
Closed -$106K – 377
2023
Q2 		$106K Sell
208
-1,155
-85% -$811K 0.02% 218
2023
Q1 		$996K Sell
1,363
-5,976
-81% -$4.34M 0.12% 162
2022
Q4 		$5.31M Buy
+7,339
New +$5.26M 1.15% 17

Other funds holding AEON

DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
FAM
Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Meteora Capital's AEON Position: Q1 2026 in Review

Meteora Capital sold out of AEON Biopharma (AEON) in Q1 2026, closing a stake of 4 shares — an estimated $4 sold.

Meteora Capital first reported a position in AEON in Q4 2022 and held it in 4 quarters. The position peaked at $5.31M in Q4 2022. 24 funds tracked by Wall St. Rank hold AEON as of Q1 2026.

  • Meteora Capital reported no remaining AEON Biopharma position as of Q1 2026 after selling out during the quarter.
  • Meteora Capital sold 4 AEON Biopharma shares in Q1 2026, an estimated $4.
  • Meteora Capital first reported a position in AEON Biopharma in Q4 2022 and held it in 4 quarters.
  • Meteora Capital's AEON Biopharma position peaked at $5.31M in Q4 2022.
  • 24 funds tracked by Wall St. Rank held AEON Biopharma as of Q1 2026.

Based on Meteora Capital's 13F filing for Q1 2026, filed 15 May 2026.